17:35 , Nov 29, 2017 |  BioCentury  |  Emerging Company Profile

Gluten-free gut

PvP Biologics Inc. is developing an oral enzyme therapy for celiac disease to break down gluten in the stomach with more specificity than a competing enzyme cocktail. The company’s KumaMax, a synthetic peptidase, should prevent...
20:41 , Jun 27, 2017 |  BC Extra  |  Financial News

Provention raises $28.4M in series A

Autoimmune and inflammatory disease prevention and interception play Provention Bio Inc. (Lebanon, N.J.) said it raised $28.4 million in a series A round from the Johnson & Johnson Innovation-JJDC Inc. arm of Johnson & Johnson...
07:00 , Mar 9, 2015 |  BC Week In Review  |  Company News

Amgen, Celimmune deal

Amgen granted Celimmune exclusive, ex-Japan rights to develop and commercialize AMG 714 . Celimmune is planning Phase II trials of the human mAb against IL-15 to treat diet non-responsive celiac disease and refractory celiac disease,...
01:42 , Mar 3, 2015 |  BC Extra  |  Company News

Celimmune licenses Amgen's celiac candidate

Amgen Inc. (NASDAQ:AMGN) granted Celimmune LLC (Bethesda, Md.) exclusive, worldwide rights outside of Japan to develop and commercialize AMG 714, a human mAb against IL-15. Amgen has an exclusive option to reacquire AMG 714 after...
07:00 , Jun 21, 2010 |  BioCentury  |  Finance

Business as usual - not!

If Genmab A/S were based in the U.S., activist investors would be demanding seats on the board and a say in the choice of a new CEO following last week's abrupt announcement that co-founder, President...
07:00 , Sep 17, 2009 |  BC Innovations  |  Targets & Mechanisms

Intercepting IL-15 in celiac disease

A group of American and Japanese researchers has shown that blocking IL-15 signaling decreased inflammation and tissue damage associated with celiac disease in mice. 1 They now hope to acquire funding to test the strategy...
07:00 , Jun 26, 2006 |  BC Week In Review  |  Clinical News

AMG 714: Additional Phase II data

Additional data from a placebo-controlled, double-blind Phase II trial in 180 patients showed that 29% of patients receiving 280 mg of AMG 714 achieved ACR50 and 14% achieved ACR70 at week 14. In patients who...
07:00 , May 22, 2006 |  BC Week In Review  |  Clinical News

AMG 714: Phase II data

Data from a double-blind, placebo controlled Phase II trial in 114 evaluable patients showed that AMG 714 missed the primary endpoint of a significantly higher proportion of patients achieving ACR20 at week 14. But more...
07:00 , Sep 12, 2005 |  BioCentury  |  Product Development

Late stage RA pipeline

Late stage RA pipeline...
07:00 , May 30, 2005 |  BioCentury  |  Finance

Ebb & Flow

Genentech...